178 related articles for article (PubMed ID: 7906316)
1. Terguride as a new anti-hyperprolactinemic agent: characterization in rats and dogs in comparison with bromocriptine.
Mizokawa T; Akai T; Nakada Y; Yamaguchi M; Nakagawa H; Hasan S; Rettig KJ; Wachtel H
Jpn J Pharmacol; 1993 Nov; 63(3):269-78. PubMed ID: 7906316
[TBL] [Abstract][Full Text] [Related]
2. Effects of bromocriptine and terguride on cell proliferation and apoptosis in the estrogen-stimulated anterior pituitary gland of the rat.
Yonezawa K; Tamaki N; Kokunai T
Neurol Med Chir (Tokyo); 1997 Dec; 37(12):901-6. PubMed ID: 9465588
[TBL] [Abstract][Full Text] [Related]
3. Terguride--a new dopamine agonist drug: a comparison of its neuroendocrine and side effect profile with bromocriptine.
Ciccarelli E; Touzel R; Besser M; Grossman A
Fertil Steril; 1988 Apr; 49(4):589-94. PubMed ID: 3127243
[TBL] [Abstract][Full Text] [Related]
4. [Effects of terguride, an ergot alkaloid derivative, on the central nervous system: biochemical and behavioral studies].
Ikoma Y; Akai T; Nakata Y; Hara K; Wachtel H; Yamaguchi M
Nihon Yakurigaku Zasshi; 1993 Aug; 102(2):113-29. PubMed ID: 8370555
[TBL] [Abstract][Full Text] [Related]
5. [Pharmacokinetic/pharmacodynamic analysis of anti-hyperprolactinemic effect of terguride based on dopamine D2 receptor occupancy].
Yamada Y; Irizuki N; Takayanagi R; Yamamoto K; Sawada Y; Iga T
Yakugaku Zasshi; 2003 Apr; 123(4):255-60. PubMed ID: 12704865
[TBL] [Abstract][Full Text] [Related]
6. [Terguride in hyperprolactinemia--experiences with 5 patients].
Wüster C; Scholz A; Schmelzle A; Horowski R; Ziegler R
Klin Wochenschr; 1990 Apr; 68(7):384-7. PubMed ID: 2188044
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological effects of BAM-1120, a novel ergoline derivative, on central dopaminergic functions in rats.
Ichihara K; Kamei H; Okumura K; Mizukoshi K; Nagasaka M
Methods Find Exp Clin Pharmacol; 1998 Sep; 20(7):561-6. PubMed ID: 9819799
[TBL] [Abstract][Full Text] [Related]
8. Effects of the partial dopamine receptor agonists SDZ 208-911, SDZ 208-912 and terguride on central monoamine receptors. A behavioral, biochemical and electrophysiological study.
Svensson K; Ekman A; Piercey MF; Hoffmann WE; Lum JT; Carlsson A
Naunyn Schmiedebergs Arch Pharmacol; 1991 Sep; 344(3):263-74. PubMed ID: 1683686
[TBL] [Abstract][Full Text] [Related]
9. Chronic treatment of pathological hyperprolactinemia and acromegaly with the new ergot derivative terguride.
Dallabonzana D; Liuzzi A; Oppizzi G; Cozzi R; Verde G; Chiodini P; Rainer E; Dorow R; Horowski R
J Clin Endocrinol Metab; 1986 Oct; 63(4):1002-7. PubMed ID: 3745401
[TBL] [Abstract][Full Text] [Related]
10. Diagnosis and drug therapy of prolactinoma.
Ciccarelli E; Camanni F
Drugs; 1996 Jun; 51(6):954-65. PubMed ID: 8736617
[TBL] [Abstract][Full Text] [Related]
11. Effect of the new ergot derivative terguride on plasma PRL and GH levels in patients with pathological hyperprolactinemia or acromegaly.
Dallabonzana D; Liuzzi A; Oppizzi G; Verde G; Chiodini PG; Dorow R; Horowski R
J Endocrinol Invest; 1985 Apr; 8(2):147-51. PubMed ID: 4031381
[TBL] [Abstract][Full Text] [Related]
12. Three-dimensional imaging of hormone-secreting cells and their microvessel environment in estrogen-induced prolactinoma of the rat pituitary gland by confocal laser scanning microscopy.
Itoh J; Kawai K; Serizawa A; Yamamoto Y; Ogawa K; Matsuno A; Watanabe K; Osamura RY
Appl Immunohistochem Mol Morphol; 2001 Dec; 9(4):364-70. PubMed ID: 11759065
[TBL] [Abstract][Full Text] [Related]
13. Changes in the prolactin serum isoforms secreted by a pituitary adenoma associated with therapy.
Morán C; Tena G; Fonseca ME; Ochoa R; Bermúdez JA; Zárate A
Arch Med Res; 1994; 25(1):1-3. PubMed ID: 8019107
[TBL] [Abstract][Full Text] [Related]
14. Effects of the dopamine agonist CV 205-502 in human prolactinomas resistant to bromocriptine.
Brue T; Pellegrini I; Gunz G; Morange I; Dewailly D; Brownell J; Enjalbert A; Jaquet P
J Clin Endocrinol Metab; 1992 Mar; 74(3):577-84. PubMed ID: 1346788
[TBL] [Abstract][Full Text] [Related]
15. Effects of dopamine d2 receptor agonists in a pituitary transplantation-induced hyperprolactinaemia/anovulation model in rats.
Moro M; Inada Y; Miyata H; Komatsu H; Kojima M; Tsujii H
Clin Exp Pharmacol Physiol; 2001 Aug; 28(8):651-8. PubMed ID: 11473532
[TBL] [Abstract][Full Text] [Related]
16. Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients.
Sabuncu T; Arikan E; Tasan E; Hatemi H
Intern Med; 2001 Sep; 40(9):857-61. PubMed ID: 11579944
[TBL] [Abstract][Full Text] [Related]
17. Effect of terguride on prolactin levels in normal, puerperal and hyperprolactinaemic women.
Venturini PL; Horowski R; Valenzano M; Costantini S; Fasce V; Gorlero F; Rainer E; De Cecco L
Eur J Clin Pharmacol; 1986; 30(2):195-7. PubMed ID: 3709645
[TBL] [Abstract][Full Text] [Related]
18. Suppression of cocaine- and food-maintained behavior by the D2-like receptor partial agonist terguride in squirrel monkeys.
Platt DM; Rodefer JS; Rowlett JK; Spealman RD
Psychopharmacology (Berl); 2003 Mar; 166(3):298-305. PubMed ID: 12589523
[TBL] [Abstract][Full Text] [Related]
19. Positive response to compound CV 205-502 in hyperprolactinemic patients resistant to or intolerant of bromocriptine.
Merola B; Sarnacchiaro F; Colao A; Di Somma C; Di Sarno A; Ferone D; Selleri A; Landi ML; Schettini G; Nappi C
Gynecol Endocrinol; 1994 Sep; 8(3):175-81. PubMed ID: 7847102
[TBL] [Abstract][Full Text] [Related]
20. Terguride, a mixed dopamine agonist-antagonist, in animal models of Parkinson's disease.
Koller WC; Herbster G
Neurology; 1987 Apr; 37(4):723-7. PubMed ID: 3561789
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]